Patheon — Merger or Acquisition (October 2012)
16 slides from Patheon's merger presentation, Oct 29, 2012
Slide 1: Patheon's Acquisition of Banner Pharmacaps
Exhibit 99.3 Patheon’s Acquisition of Banner Pharmacaps Building the Pharmaceutical Industry’s Leading Contract Development & Manufacturing Organization October 29, 2012
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements or information which reflect our expectations regarding possible events, conditions, our future growth, results of operations, performance, and business prospects and opportunities. All statements, other than statements
Slide 3: Transaction Overview
Transaction Overview • Patheon to acquire Banner Pharmacaps, a specialty pharmaceutical Transaction company dedicated to the research, development and manufacturing of unique gelatin-based dosage forms • Total consideration to amount to USD 255 million, subject to Consideration adjustments • Committ
Slide 4: Strategic Rationale
Strategic Rationale • Banner is the world’s second largest pharmaceutical business in manufacturing softgels for OTC, prescription and nutritional consumer products • Leader in fast-growing complementary technology with a broad product and intellectual property portfolio • Owns state-of-the-art faci
Slide 5: Banner Acquisition is Consistent with our Strategy
Banner Acquisition is Consistent with our Strategy STRENGTHEN CORE SELL BUSINESS OPERATIONS DIFFERENTLY • Increases capability and scale in • Higher margins from proprietary complex solid dosage formats technologies and products • Provides immediate access to Latin America market with Mexico facilit
Slide 6: Growing Market Share in a Highly Fragmented Marketplace
Growing Market Share in a Highly Fragmented Marketplace $1.4 B $12.3 B (+7.5%) (+5%) 1.4 12 All Other (52%) 100+ Others (47%) LTS (2%) 1.2 Catalent (3%) 10 Corden Pharma (2%) AAIPharma (4%) Hospira (2%) 1.0 Aptuit (6%) 8 Recipharm (2%) PPD (6%) Aenova (3%) 0.8 Haupt (3%) SGS (8%) 6 0.6 Vetter (4%) L
Slide 7: Softgel Market has Experienced Continued Growth Historically
Softgel Market has Experienced Continued Growth Historically U.S. Softgel Market CAGR U.S. Softgel Market CAGR Billion units 07-11 Billion $ 07-11 6% 3% 5.4 7.7 4.9 7.4 18% 1.4 0.8 18% 0.6 4.3 1.0 6.7 0.4 0.7 8% 0.6 0.7 0.5 1.4 1.4 4% 1.2 6.1 6.2 2% 5.7 2.4 2.5 2.6 2% 2007 2009 2011 2007 2009 2011 R
Slide 8: Banner's Proprietary Softgel Technologies
Banner’s Proprietary Softgel Technologies Type of Technology Main Features • Attractive dosage form for pediatric and geriatric patients • Masks tastes and odors • Non-animal based gelatin alternative • pH and heat tolerant • Enteric feature reduces reflux and gastric irritation • Entericfeatures li
Slide 9: Expanded Global Network
Expanded Global Network Tilburg, The Netherlands Swindon, England Toronto, Canada (CMO/softgel) (PDS, CMO sterile) (PDS, CMO solids) Whitby, Canada (PDS, CMO solids) Olds, Alberta Canada (CMO) Milton Park, England (PDS development) (included in Swindon) High Point, USA (R&D, CMO) Monza, Italy RTP, U
Slide 10: Financial Impact
Financial Impact • Total consideration is USD 255 million, subject to adjustments • Committed financing for transaction value, associated expenses and repayment of existing debt, and for general corporate purposes • We expect that Patheon’s Adjusted EBITDA margin will benefit from the integration of
Slide 11: Quarterly Adjusted EBITDA and EBITDA per Debt Commitment Letter
Quarterly Adjusted EBITDA and EBITDA per Debt Commitment Letter U.S.D., in millions Actual results Estimated results Q1'12 Q2'12 Q3'12 Q4'12 FYE'12 Adjusted EBITDA (9.2) 9.7 34.6 33.9 69.0 Non-cash items 0.7 1.3 0.4 0.9 3.3 Consulting fees 6.3 6.0 1.0 0.0 13.3 Other items 0.4 2.4 0.0 0.0 2.8 Pro for
Slide 12: W Perfomance the World Over
W Perfomance the World Over
Slide 13: Building the Pharmaceutical Industry's Leading Contract Development & Manufacturing Organization
Building the Pharmaceutical Industry’s Leading Contract Development & Manufacturing Organization • Adds well-balanced product and intellectual property portfolio with complementary technology platforms Combination • Builds scale, expands capacity and broadens footprint in emerging markets • Expected
Slide 14: Appendix
Appendix cP atheon Perfomance the World Over
Slide 15: U.S. Non-GAAP Reconciliation
U.S. Non-GAAP Reconciliation Adjusted EBITDA (U.S.D., in millions) (unaudited) Actuals Estimate Q1 2012 Q2 2012 Q3 2012 Q4 2012 Full Year Adjusted EBITDA (9.2) 9.7 34.6 33.9 69.0 Depreciation and amortization (10.6) (10.8) (9.3) (9.9) (40.6) Repositioning expenses (0.8) (6.0) (0.1) 1.7 (5.2) Interes
Slide 16: U.S. Non-GAAP Reconciliation
U.S. Non-GAAP Reconciliation EBITDA per the Debt Commitment Letter (U.S.D., in millions) Actuals Estimate (unaudited) Q1 2012 Q2 2012 Q3 2012 Q4 2012 Full Year EBITDA per the Debt Commitment Letter 139.7 Estimated Banner pro forma adjusted EBITDA (1) (25.0) (1) Represents Banner Pharmacaps expected